IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of Notice published in newspapers25-08-2021
25-08-2021
Earnings Call for Q1FY22 of IOL Chemicals and Pharmaceuticals
Conference Call with IOL Chemicals and Pharma Management and Analysts on Q1FY22 Performance and Outlook. Listen to the full earnings transcript.20-08-2021
IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation Q1 FY2219-08-2021
IOL Chemicals & Pharmaceuticals Ltd - 524164 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that subsequent to declaration of financial results for the quarter ended 30th June 2021, the Company is organizing an analyst / investors conference call on Friday, 20th August 2021 at 12:00 noon (IST) to discuss the financial performance of the Company for the Q1 FY22. The invite of the same is attached herewith.19-08-2021
IOL Chemicals & Pharmaceuticals Ltd - 524164 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of duplicate share certificates16-08-2021
IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of newspaper publication of audited financial results for the quarter ended 30th June 202116-08-2021
Q1FY22 Result Announced for IOL Chemicals and Pharmaceuticals Ltd.
Highlights IOL Chemicals and Pharmaceuticals Limited a leading manufacturer of pharmaceutical (APIs) and specialty chemicals today posted its financial results for the quarter ending 30th June 2021. The Company on QoQ & YoY basis recorded 12% growth in total income, however the EBITDA has been almost flat on QoQ and declined by about 27% on YoY basis on account of stressed demand primarily due to 2nd wave of Covid-19 globally. Dr Sanjay Chaturvedi, Chief Executive Officer said “During the quarter ended June 2021, the Company’s performance has been satisfactory in spite of difficult operating conditions faced by the Company during surged situation of Covid-19 pandemic. The Chemicals segment performed very well during the quarter both in terms of top line and bottom line. He also added, the Company completed the installation of new manufacturing facilities ‘Unit -10’ to manufacture multiple Pharma (API’s) products including Fenofibrate, Lamotrigine and Ursodeoxycholic Acid (UDCA) to cater the growing demand. Talking about future projects, he added that the installation of new manufacturing facilities 'Unit -9' for manufacturing Gabapentin & other pharma (APIs) products is slightly delayed of its schedule due to 2nd wave of Covid-19 and expected to complete in 3rd quarter of FY22 without any cost overrun." Result PDF16-08-2021
IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - 34Th Annual General Meeting (AGM) On The Saturday, 18Th September 2021
Fixed the 34th Annual General Meeting (AGM) of the members of the Company to be held on the Saturday, 18th September 2021 through Video Conferencing/ Other Audio Visual Means ('VC/OAVM') Facility.13-08-2021
IOL Chemicals & Pharmaceuticals Ltd - 524164 - Purpose Of AGM Of The Company And To Determine The Members Eligible To Receive Dividend.
Fixed the record date 11th September 2021 for the purpose of AGM of the Company and to determine the members eligible to receive dividend.13-08-2021